Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 86 points (-0.5%) at 16,084 as of Friday, April 11, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,014 issues advancing vs. 1,941 declining with 158 unchanged. The Health Care sector currently sits down 0.7% versus the S&P 500, which is down 0.3%. Top gainers within the sector include Gilead ( GILD), up 4.5%, Merck ( MRK), up 0.8%, Biogen Idec ( BIIB), up 0.7%, Celgene Corporation ( CELG), up 0.7% and Amgen ( AMGN), up 0.6%. On the negative front, top decliners within the sector include Perrigo Company ( PRGO), down 1.8%, Shire ( SHPG), down 1.5%, Pfizer ( PFE), down 1.2%, Novartis ( NVS), down 1.0% and AstraZeneca ( AZN), down 0.9%. TheStreet would like to highlight 3 stocks pushing the sector higher today: 3. Allergan ( AGN) is one of the companies pushing the Health Care sector higher today. As of noon trading, Allergan is up $4.12 (3.5%) to $120.75 on heavy volume. Thus far, 2.4 million shares of Allergan exchanged hands as compared to its average daily volume of 2.7 million shares. The stock has ranged in price between $116.00-$121.96 after having opened the day at $116.47 as compared to the previous trading day's close of $116.63. Allergan, Inc. operates as a multi-specialty health care company primarily in the United States, Europe, Latin America, and the Asia Pacific. Allergan has a market cap of $36.2 billion and is part of the drugs industry. Shares are up 5.0% year-to-date as of the close of trading on Thursday. Currently there are 9 analysts who rate Allergan a buy, no analysts rate it a sell, and 7 rate it a hold. TheStreet Ratings rates Allergan as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, notable return on equity and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Allergan Ratings Report now. 3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.